Autres langues GlycoNex Incorporation

Actions

4168

TW0004168000

Recherche biotechnologique et médicale

Cours en clôture Taipei Exchange 19/08/2026			Varia. 5j.	Varia. 1 janv.
22,50 ^TWD	+0,90%		-1,75%	-12,62%

13/08	GlycoNex Incorporation publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI
03/08	GlycoNex Inc administre la première dose au premier patient de l'essai de phase I du GNX1021	CI

Autres langues

13/08	GlycoNex Incorporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
03/08	GlycoNex Inc Doses First Patient In Phase I Trial Of GNX1021
11/06	Glyconex Announces Positive Topline Results for Phase III Clinical Trial of Denosumab Biosimilar Spd8
14/05	GlycoNex Incorporation Reports Earnings Results for the First Quarter Ended March 31, 2026
14/04	GlycoNex, Inc Receives PMDA Approval To Initiate First-In-Human Phase 1 Trial Of GNX1021 In Gastrointestinal Cancers
23/03	GlycoNex Inc. And Nippon Kayaku Co., Ltd. Enters Collaboration To Advance Next-Generation ADC Candidate
13/03	GlycoNex Incorporation Reports Earnings Results for the Full Year Ended December 31, 2025
08/12	GlycoNex Signs CDMO Service Agreement with Change Cure to Advance HMGB1-Targeted Antibody Program
24/11	Glyconex, Inc. and Hokkaido University Hospital Launch Study to Advance Glycan-Directed ADC Development in Gastric Cancer
14/11	GlycoNex Incorporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025
29/10/25	GlycoNex announces last patient dosed in phase 3 trial of SPD8, a denosumab biosimilar for osteoporosis
29/10/25	GlycoNex, Inc. Announces Last Patient Dosed in Phase 3 Trial of SPD8, a Denosumab Biosimilar for Osteoporosis
13/08/25	GlycoNex Incorporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025
12/06/25	GlycoNex, Inc. Announces Publication of Preclinical Study on Gnx1021, A Novel Glycan-Targeted Adc for Gastric Cancer
27/05/25	GlycoNex, Inc. Announces Publication of Research Involving Pro-Antibody, GNX201, in the International Journal of Biological Macromolecules
12/05/25	GlycoNex Incorporation Reports Earnings Results for the First Quarter Ended March 31, 2025
14/03/25	GlycoNex Incorporation Reports Earnings Results for the Full Year Ended December 31, 2024
10/01/25	Recent Ustekinumab And Denosumab Biosimilars Deals
06/01/25	Glyconex, Inc. Announces Licensing Agreement for Spd8 Biosimilar
17/12/24	GlycoNex Announces First Patient Dosed in Phase 3 Clinical Trial for Denosumab Biosimilar
12/11/24	GlycoNex Incorporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024
16/08/24	Glyconex Incorporation Completes the First Phase Trial of Biosimilar Drug Spd8 and Will Start the Third Phase Clinical Trial
12/08/24	GlycoNex Incorporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024
28/05/24	Glyconex and Precisemab Sign Technology Licensing Agreement to Advance Development of Novel Anti-Glycan Antibodies for Cancer Therapy
14/05/24	GlycoNex Incorporation Reports Earnings Results for the First Quarter Ended March 31, 2024